# US Specialty Formulations LLC - Inspection Records

Source: https://www.keypedia.com/companies/us-specialty-formulations-llc/2a5dd57a-6a0b-44a4-88ec-d642f91d1315

> Inspection records and compliance data for US Specialty Formulations LLC in Allentown, Pennsylvania. Access full analysis and detailed observations.

---

## Details

- Name: US Specialty Formulations LLC
- FEI Number: 3010680515
- City: Allentown
- State: Pennsylvania
- Country Name: United States
- Address Line 1: 1401 S Albert St
- Zip Code: 18103

## Related Documents

- [483 - US Specialty Formulations LLC - Unknown Date](https://www.keypedia.com/records/483/us-specialty-formulations-llc/4dd416c3-7118-437a-bcb5-8ca83ae76b15) — source: FDA, date: Invalid Date
- [483 - US Specialty Formulations LLC - 2026-01-14](https://www.keypedia.com/records/483/us-specialty-formulations-llc/48b75557-852b-44d0-b313-616e9c14b667) — source: FDA, date: January 14, 2026
- [FDA Inspection 1298396 - US Specialty Formulations LLC - 2026-01-14](https://www.keypedia.com/records/fda_inspections/us-specialty-formulations-llc/e72c419c-3eb9-4794-a8df-38ab824d37c6) — source: FDA, date: January 14, 2026
- [483 - US Specialty Formulations LLC - 2025-03-26](https://www.keypedia.com/records/483/us-specialty-formulations-llc/a05165b7-ed9d-4680-b279-3e464026ec25) — source: FDA, date: March 26, 2025
- [FDA Inspection 1265449 - US Specialty Formulations LLC - 2025-03-26](https://www.keypedia.com/records/fda_inspections/us-specialty-formulations-llc/e25bcef3-888a-4f3e-b64b-223257e43fa2) — classification: Voluntary Action Indicated (VAI), source: FDA, date: March 26, 2025
- [483 - US Specialty Formulations LLC - 2024-07-02](https://www.keypedia.com/records/483/us-specialty-formulations-llc/02180e72-25a9-4bdf-970c-9567cf7a7ce8) — source: FDA, date: July 2, 2024
- [FDA Inspection 1243882 - US Specialty Formulations LLC - 2024-07-02](https://www.keypedia.com/records/fda_inspections/us-specialty-formulations-llc/dd9ee101-2a34-4453-ad4e-ba79c9bf11c3) — classification: Official Action Indicated (OAI), source: FDA, date: July 2, 2024
- [483 - US Specialty Formulations LLC - 2022-04-26](https://www.keypedia.com/records/483/us-specialty-formulations-llc/2ff0d13c-a3ce-40eb-ad34-b5b1e999f613) — source: FDA, date: April 26, 2022
- [FDA Inspection 1167934 - US Specialty Formulations LLC - 2022-04-26](https://www.keypedia.com/records/fda_inspections/us-specialty-formulations-llc/737bef48-423a-4dcc-92af-ca91074c2095) — classification: Official Action Indicated (OAI), source: FDA, date: April 26, 2022
- [FDA Inspection 1167934 - US Specialty Formulations LLC - 2022-04-26](https://www.keypedia.com/records/fda_inspections/us-specialty-formulations-llc/c2529d65-9b9a-4df4-95ab-aed2f8190c7d) — classification: Official Action Indicated (OAI), source: FDA, date: April 26, 2022
- [FDA Inspection 1097950 - US Specialty Formulations LLC - 2019-07-23](https://www.keypedia.com/records/fda_inspections/us-specialty-formulations-llc/d3651a69-ca0b-4e10-a392-9496baabe17c) — classification: Official Action Indicated (OAI), source: FDA, date: July 23, 2019
- [FDA Inspection 1023411 - US Specialty Formulations LLC - 2017-08-29](https://www.keypedia.com/records/fda_inspections/us-specialty-formulations-llc/33cfa969-db8c-466f-a448-732a50bd78d8) — classification: Official Action Indicated (OAI), source: FDA, date: August 29, 2017
- [FDA Inspection 928445 - US Specialty Formulations LLC - 2015-05-29](https://www.keypedia.com/records/fda_inspections/us-specialty-formulations-llc/5d7280bc-635f-46cf-a2e4-4cc7a960a004) — classification: Official Action Indicated (OAI), source: FDA, date: May 29, 2015
- [FDA Inspection 871574 - US Specialty Formulations LLC - 2014-03-18](https://www.keypedia.com/records/fda_inspections/us-specialty-formulations-llc/99f409a5-5f1d-436e-8b47-ab3de37814d4) — classification: No Action Indicated (NAI), source: FDA, date: March 18, 2014

## Related Companies

- [Chunghwa Chemical Synthesis & Biotech Co., Ltd](https://www.keypedia.com/companies/chunghwa-chemical-synthesis-biotech-co-ltd/4c8ab291-0275-4884-960a-f5b3bc604eff)
- [Hetero Drugs Ltd. - Unit 1](https://www.keypedia.com/companies/hetero-drugs-ltd-unit-1/4c15935a-9ff7-4f66-b649-3d78aa3e9753)
- [Novo Nordisk US Bio Production Inc.](https://www.keypedia.com/companies/novo-nordisk-us-bio-production-inc/08f5214b-4db0-4d94-86ee-4ba9c3c28ea2)
- [BASF SE](https://www.keypedia.com/companies/basf-se/96b65069-a37b-4a26-9655-5f310b60cc6f)
- [Kumar Organic Products Ltd.](https://www.keypedia.com/companies/kumar-organic-products-ltd/acc61a81-a684-4eb3-a4c8-d487dc0164e5)
- [Sri Krishna Pharmaceuticals Limited](https://www.keypedia.com/companies/sri-krishna-pharmaceuticals-limited/5afbb0e4-2595-4bfc-8ecd-7c0d9deb8b38)
- [PharmaZell GmbH](https://www.keypedia.com/companies/pharmazell-gmbh/37149959-807d-41b5-be90-cc07ca5a6098)
- [Sichuan Qingmu Pharmaceutical Co., Ltd](https://www.keypedia.com/companies/sichuan-qingmu-pharmaceutical-co-ltd/821a1489-2969-47a3-8321-b97728ac795a)
- [Dasami Lab Private Limited](https://www.keypedia.com/companies/dasami-lab-private-limited/950d9812-d647-4e9e-ad9a-01eab0ebe091)
- [Sri Krishna Pharmaceuticals Limited - Unit IV](https://www.keypedia.com/companies/sri-krishna-pharmaceuticals-limited-unit-iv/fd405e8b-b747-4adb-bbb5-da63c0cfa56b)

## Related Officers

- [John R. Tuohig](https://www.keypedia.com/people/john-r-tuohig/4f66f546-2398-424b-a3a1-f646331af5a2)
- [Deputy Director](https://www.keypedia.com/people/lori-m-newman/a0e448e4-11ba-4095-b879-feabb8750b3f)
- [Ucheabuchi C. Chudi-nwankwor](https://www.keypedia.com/people/ucheabuchi-c-chudi-nwankwor/18b01d08-3cfd-4ace-97b2-5f54b6427661)
- [Consumer Safety Officer](https://www.keypedia.com/people/christina-k-theodorou/3c18d958-14de-4f25-9fbd-7358205155f7)
- [Investigator](https://www.keypedia.com/people/lu-chen/d0700911-c592-4da7-a445-5dfb2a4bedff)